The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. AbCellera Biologics's current ratio for the quarter that ended in Dec. 2023 was 7.33.
AbCellera Biologics has a current ratio of 7.33. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for AbCellera Biologics's Current Ratio or its related term are showing as below:
ABCL'
s Current Ratio Range Over the Past 10 Years
Min: 1.6 Med: 7.52 Max: 8.67
Current: 7.33
During the past 6 years, AbCellera Biologics's highest Current Ratio was 8.67. The lowest was 1.60. And the median was 7.52.
ABCL's Current Ratio is ranked better than 74.03% of 1552
companies
in the Biotechnology industry
Industry Median: 3.78
vs ABCL: 7.33
AbCellera Biologics Current Ratio Historical Data
The historical data trend for AbCellera Biologics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AbCellera Biologics's Current Ratio
For the Biotechnology subindustry, AbCellera Biologics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics's Current Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Current Ratio distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Current Ratio falls into.
AbCellera Biologics Current Ratio Calculation
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
AbCellera Biologics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (NAS:ABCL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
AbCellera Biologics Current Ratio Related Terms
Thank you for viewing the detailed overview of AbCellera Biologics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
AbCellera Biologics (AbCellera Biologics) Business Description
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABCL has been successfully added to your 